First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer.

Budd, G. Thomas; Barlow, William; Moore, Halle C. F.; Hobday, Timothy J.; Stewart, James A.; Isaacs, Claudine; Salim, Michael; Cho, J. K.; Rinn, Kristine; Albain, Kathy S.; Chew, Helen K.; Burton, Gary V.; Moore, T; Srkalović, Gordan; McGregor, B. A.; Flaherty, Lawrence E.; Livingston, R. B.; Lew, Danika; Gralow, JR; Hortobágyi, G. N.; Swog,

doi:10.1200/jco.2011.29.15_suppl.1004

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, SWOG S0221 conducted a 2×2 design phase III trial comparing AC+G (filgrastim) versus dd AC in different combinations with either dd T (paclitaxel) for 6 cycles or weekly T for a total of 12 weeks. This trial showed equivalent progression free survival (PFS) in both weekly and 2 weekly T (82% in weekly versus 81% in dd PFS), suggesting that weekly paclitaxel could have the same efficacy without the patients having to receive the growth factor support 27 . A Spanish group published the results from the GEICAM/2003-02 study, comparing FAC, and FAC followed by weekly paclitaxel for node negative high-risk patients.…”

Section: Adjuvant Treatment In Hormone Receptor Positive Breast Cancementioning

confidence: 87%

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy

et al. 2014

View full text Add to dashboard Cite

Breast cancer is the most commonly diagnosed cancer in women. The latest world cancer statistics calculated by the International Agency for Research on Cancer (IARC) revealed that 1,677,000 women were diagnosed with breast cancer in 2012 and 577,000 died. The TNM classification of malignant tumor (TNM) is the most commonly used staging system for breast cancer. Breast cancer is a group of very heterogeneous diseases. The molecular subtype of breast cancer carries important predictive and prognostic values, and thus has been incorporated in the basic initial process of breast cancer assessment/diagnosis. Molecular subtypes of breast cancers are divided into human epidermal growth factor receptor 2 positive (HER2 +), hormone receptor positive (estrogen or progesterone +), both positive, and triple negative breast cancer. By virtue of early detection via mammogram, the majority of breast cancers in developed parts of world are diagnosed in the early stage of the disease. Early stage breast cancers can be completely resected by surgery. Over time however, the disease may come back even after complete resection, which has prompted the development of an adjuvant therapy. Surgery followed by adjuvant treatment has been the gold standard for breast cancer treatment for a long time. More recently, neoadjuvant treatment has been recognized as an important strategy in biomarker and target evaluation. It is clinically indicated for patients with large tumor size, high nodal involvement, an inflammatory component, or for those wish to preserve remnant breast tissue. Here we review the most up to date conventional and developing treatments for different subtypes of early stage breast cancer.

show abstract

Section: Adjuvant Treatment In Hormone Receptor Positive Breast Cancementioning

confidence: 87%

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In the present evidence review, trials of taxanes represented the largest number of rcts (fifty-five trials in ninety-three publications) and are summarized in Supplemental Table 3 21,27-30,35,36, [49][50][51][52][53][54] . Because taxane studies are relatively recent, our database search found most of the published trials cited in other reviews or meta-analyses.…”

Section: Taxanesmentioning

confidence: 99%

Adjuvant Chemotherapy for Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline

et al. 2015

View full text Add to dashboard Cite

chemotherapy is not recommended for the adjuvant treatment of breast cancer in any patient population. Anthracycline-taxane-based polychemotherapy regimens are, overall, considered superior to earliergeneration regimens and have the most significant impact on patient survival outcomes. Regimens with varying anthracycline and taxane doses and schedules are options; in general, paclitaxel given every 3 weeks is inferior. Evidence does not support the use of bevacizumab in the adjuvant setting; other systemic therapy agents such as metformin and vaccines remain investigatory. Adjuvant bisphosphonates for menopausal women will be discussed in later work. ConclusionsThe results of this systematic review constitute a comprehensive compilation of the high-level evidence that is the basis for the 2014 pebc guideline on systemic therapy for early breast cancer. Use of cytotoxic chemotherapy is presented here; the results addressing endocrine therapy and her2-targeted treatment, and the final clinical practice recommendations, are published separately in this supplement.

show abstract